Compare Dishman Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PROCTER & GAMBLE HEALTH DISHMAN PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 25.1 53.6 46.8% View Chart
P/BV x 3.3 4.7 71.8% View Chart
Dividend Yield % 0.7 10.2 6.5%  

Financials

 DISHMAN PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PROCTER & GAMBLE HEALTH
Dec-18
DISHMAN PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3743,549 10.5%   
Low Rs1291,301 9.9%   
Sales per share (Unadj.) Rs197.8511.4 38.7%  
Earnings per share (Unadj.) Rs21.261.3 34.6%  
Cash flow per share (Unadj.) Rs34.774.0 46.9%  
Dividends per share (Unadj.) Rs2.00440.00 0.5%  
Dividend yield (eoy) %0.818.1 4.4%  
Book value per share (Unadj.) Rs179.9927.8 19.4%  
Shares outstanding (eoy) m80.6916.60 486.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.7 26.8%   
Avg P/E ratio x11.939.6 30.0%  
P/CF ratio (eoy) x7.232.8 22.1%  
Price / Book Value ratio x1.42.6 53.5%  
Dividend payout %9.4717.9 1.3%   
Avg Mkt Cap Rs m20,30640,257 50.4%   
No. of employees `0000.81.1 73.1%   
Total wages/salary Rs m5,3551,313 407.9%   
Avg. sales/employee Rs Th19,252.77,486.7 257.2%   
Avg. wages/employee Rs Th6,459.51,157.6 558.0%   
Avg. net profit/employee Rs Th2,064.1897.2 230.1%   
INCOME DATA
Net Sales Rs m15,9618,490 188.0%  
Other income Rs m265244 108.8%   
Total revenues Rs m16,2268,734 185.8%   
Gross profit Rs m4,1031,482 276.9%  
Depreciation Rs m1,091211 516.4%   
Interest Rs m9440-   
Profit before tax Rs m2,3341,514 154.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m624563 110.9%   
Profit after tax Rs m1,7111,017 168.2%  
Gross profit margin %25.717.5 147.3%  
Effective tax rate %26.737.1 71.9%   
Net profit margin %10.712.0 89.5%  
BALANCE SHEET DATA
Current assets Rs m11,01815,343 71.8%   
Current liabilities Rs m9,5171,960 485.5%   
Net working cap to sales %9.4157.6 6.0%  
Current ratio x1.27.8 14.8%  
Inventory Days Days11049 226.7%  
Debtors Days Days3528 122.5%  
Net fixed assets Rs m16,3041,209 1,348.2%   
Share capital Rs m161166 97.2%   
"Free" reserves Rs m12,90715,235 84.7%   
Net worth Rs m14,51615,401 94.2%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80517,595 169.4%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 111.0%   
Return on assets %8.95.8 154.1%  
Return on equity %11.86.6 178.4%  
Return on capital %17.510.3 170.9%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9521,636 302.6%   
Fx outflow Rs m6974,368 16.0%   
Net fx Rs m4,255-2,732 -155.7%   
CASH FLOW
From Operations Rs m2,786-1,304 -213.7%  
From Investments Rs m-1,52912,697 -12.0%  
From Financial Activity Rs m-941-301 313.2%  
Net Cashflow Rs m31611,093 2.9%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.7 18.2 20.3%  
FIIs % 12.7 1.0 1,270.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 29.1 75.9%  
Shareholders   46,261 28,591 161.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS